Xeris Biopharma (NASDAQ:XERS) Insider Sells $250,000.00 in Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Kevin McCulloch sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, September 28th. The stock was sold at an average price of $10.00, for a total transaction of $250,000.00. Following the sale, the insider directly owned 1,614,208 shares of the company’s stock, valued at approximately $16,142,080. This trade represents a 1.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kevin Mcculloch also recently made the following trade(s):

• On Tuesday, September 1st, Kevin McCulloch sold 15,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.49, for a total transaction of $127,350.00.
• On Monday, August 3rd, Kevin McCulloch sold 15,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.02, for a total transaction of $120,300.00.
• On Wednesday, July 1st, Kevin McCulloch sold 90,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.03, for a total transaction of $722,700.00.

Xeris Biopharma Trading Up 1.5%

Shares of Xeris Biopharma stock traded up $0.15 on Tuesday, hitting $9.98. 19,292,234 shares of the company’s stock traded hands, compared to its average volume of 1,973,664. The firm’s 50-day moving average price is $8.38 and its two-hundred day moving average price is $7.20. The stock has a market capitalization of $1.82 billion, a PE ratio of -90.73 and a beta of 0.70. Xeris Biopharma Holdings, Inc. has a one year low of $5.25 and a one year high of $11.33. The company has a debt-to-equity ratio of 17.00, a current ratio of 1.45 and a quick ratio of 1.02.

Xeris Biopharma (NASDAQ:XERS) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by ($0.19). Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%.The company had revenue of $92.10 million during the quarter, compared to the consensus estimate of $90.12 million. On average, research analysts expect that Xeris Biopharma Holdings, Inc. will post 0.07 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Weiss Ratings lowered Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Leerink Partners increased their price target on shares of Xeris Biopharma from $12.00 to $16.00 and gave the company an “outperform” rating in a research report on Thursday, September 10th. Barclays lifted their price objective on shares of Xeris Biopharma from $9.00 to $12.00 and gave the stock an “overweight” rating in a research note on Thursday, August 20th. Finally, Wall Street Zen upgraded shares of Xeris Biopharma from a “hold” rating to a “buy” rating in a report on Saturday, September 19th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $12.80.

Institutional Trading of Xeris Biopharma

Several hedge funds have recently added to or reduced their stakes in XERS. KBC Group NV acquired a new position in Xeris Biopharma in the first quarter valued at about $27,000. Allworth Financial LP bought a new position in shares of Xeris Biopharma during the 2nd quarter valued at about $34,000. State of Wyoming bought a new stake in Xeris Biopharma during the 2nd quarter worth approximately $52,000. Integrated Wealth Concepts LLC bought a new stake in Xeris Biopharma during the 2nd quarter worth approximately $74,000. Finally, Kingsview Wealth Management LLC acquired a new stake in Xeris Biopharma during the 4th quarter worth approximately $78,000. Institutional investors and hedge funds own 42.75% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc (NASDAQ:XERS) is a specialty pharmaceutical company focused on developing and commercializing therapies using proprietary formulation and drug-delivery technologies. Its platforms, including XeriSol and XeriJect, are designed to enable liquid or ready-to-use formulations of medicines that may otherwise require refrigeration, reconstitution, or administration by a healthcare professional.

The company’s commercial products include Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia; Keveyis (dichlorphenamide), an oral therapy for primary periodic paralysis; and Recorlev (levoketoconazole), an oral treatment for endogenous hypercortisolemia in adults with Cushing’s syndrome.